Silver Book Fact

In individuals with persistent low back pain, tanezumab, a humanized anti-nerve growth factor antibody, showed clinical and statistical analgesic efficacy that was superior to placebo and naproxen.

Katz, Nathaniel, David G Borenstein, Charles Birbara, Candace Bramson, Mary Anne Nemeth, Mike D Smith, and Mark T Brown. Efficacy and Safety of Tanezumab in the Treatment of Chronic Low Back Pain. Pain. 2011; 152(10): 2248-58. http://www.painjournalonline.com/article/S0304-3959%2811%2900316-2/abstract

Reference

Title
Efficacy and Safety of Tanezumab in the Treatment of Chronic Low Back Pain
Publication
Pain
Publication Date
2011
Authors
Katz, Nathaniel, David G Borenstein, Charles Birbara, Candace Bramson, Mary Anne Nemeth, Mike D Smith, and Mark T Brown
Volume & Issue
Volume 152, Issue 10
Pages
2248-58
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Nerve growth factor (NGF) has been found to be a major mediator of inflammatory and neuropathic pain and provides a new therapeutic target.  
  • Pregalbin, an antiepileptic drug, produced around a 32% pain reduction (a significant reduction) at week 16 versus around 20% for placebo, in patients with neuropathic pain due to spinal cord…  
  • The Mayo Clinic Pain Rehabilitation Center helps people with persistent pain return to an active lifestyle and has found that among patients who finish the program, nearly 84% report greater…  
  • Acupuncture, in combination with routine care, was associated with marked clinical improvements in patients with persistent low back pain. It has also shown improvement in primary and secondary outcomes…  
  • Researchers have developed several sub-types of ion channels that allow inflammation and growth factors to trigger persistent pain.